The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 02, 2018

Filed:

May. 13, 2013
Applicant:

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

John P. Cogswell, Yardley, PA (US);

Stacie M. Goldberg, Potomac, MD (US);

Ashok Kumar Gupta, Clarksburg, MD (US);

Maria Jure-Kunkel, Plainsboro, NJ (US);

Xi-Tao Wang, Wellesley, MA (US);

Jon M. Wigginton, Rockville, MD (US);

Assignee:

Bristol-Myers Squibb Company, Princeton, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2818 (2013.01); A61K 39/3955 (2013.01); C07K 16/18 (2013.01); C07K 16/2803 (2013.01); C07K 16/2827 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/76 (2013.01); G01N 2333/70596 (2013.01); G01N 2800/52 (2013.01);
Abstract

The disclosure provides a method for immunotherapy of a cancer patient, comprises administering to the patient an Ab that inhibits signaling from the PD-1/PD-L1 signaling pathway, or a combination of such Ab and an anti-CTLA-4 Ab. This disclosure also provides a method for immunotherapy of a cancer patient comprising selecting a patient who is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the patient that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering an anti-PD-1 Ab to the selected subject. The disclosure additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.


Find Patent Forward Citations

Loading…